<![CDATA[FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer]]>
RegulatoryapprovedgedatolisibPositive
AI Analysis
Summary
The FDA has approved gedatolisib combinations for treating HR+/HER2– PIK3CA wild-type advanced breast cancer in patients with prior CDK4/6 inhibitor treatment, based on positive phase 3 VIKTORIA-1 trial results.
Clinical Trial Data
Phase
3
Outcome Details
FDA approval for gedatolisib combinations in HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i based on phase 3 VIKTORIA-1 trial
Importance:8/10
Sentiment:
0.85
oncologybreast cancerFDA approvalphase 3VIKTORIA-1
Read the original article
Published by Cancer Network on July 14, 2026 7:25 PM